Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors

OBJECTIVES: Although many newer diabetes medications have become available in the last decade, most have not been widely studied in populations with chronic kidney disease under routine care. Linagliptin, a recently marketed dipeptidyl peptidase 4 (DPP‐4) inhibitor, is the only agent in the U.S. tha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocrinol Diabetes Metab
Main Authors: Patorno, Elisabetta, Gopalakrishnan, Chandrasekar, Bartels, Dorothee B., Brodovicz, Kimberly G., Liu, Jun, Schneeweiss, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360917/
https://ncbi.nlm.nih.gov/pubmed/30815542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados